Sentinel node mapping in the prostate cancer: Meta-analysis;Mapping der wächterlymphknoten beim prostatakarzinom

NuklearMedizin

Volumn 50, Issue 3, 2011, Pages 107-115

  Sadeghi, R ^a   Tabasi, K T ^b   Bazaz, S M M ^c   Kakhki, V R D ^a   Massoom, A F ^c   Gholami, H ^c   Zakavi, S R ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Lympho scintigraphy; Meta analysis; Prostate cancer; Sentinel node biopsy

Indexed keywords

HUMAN SERUM ALBUMIN COLLOID TC 99M; HUMAN SERUM ALBUMIN TC 99M; NANOCOLL TC 99M; PHYTATE TC 99M; TECHNETIUM SULFUR COLLOID TC 99M; UNCLASSIFIED DRUG;

DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; META ANALYSIS; PELVIS LYMPH NODE; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; HUMANS; INCIDENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 79957658273     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0339-10-07     Document Type: Review

References (60)

1. www.cebm.net/index.aspx?o=1025.
2. Bader P, Burkhard FC, Markwalder R et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168: 514-518.
3. Beheshti M, Imamovic L, Broinger G et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254: 925-933.
4. Beri A, Janetschek G. Technology insight: radioguided sentinel lymph node dissection in the staging of prostate cancer. Nat Clin Pract Urol 2006; 3: 602-610.
5. Brenot-Rossi I, Bastide C. Commentary on: Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2000 patients. Eur J Nucl Med Mol Imaging 2009; 36: 1375-1376.
6. Brenot-Rossi I, Rossi D, Esterni B et al. Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: influence of the dose of radiolabelled colloid to avoid failure of the procedure. Eur J Nucl Med Mol Imaging 2008; 35: 32-38.
7. Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003; 169: 145-148.
8. Corvin S, Schilling D, Eichhorn K et al. Laparoscopic sentinel lymph node dissection - a novel technique for the staging of prostate cancer. Eur Urol 2006; 49: 280-285.
9. Crawshaw JW, Hadway P, Hoffland D et al. Sentinel lymph node biopsy using dynamic lymphoscintigraphy combined with ultrasound-guided fine needle aspiration in penile carcinoma. Br J Radiol 2009; 82: 41-48.
10. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
11. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634.
12. Fukuda M, Egawa M, Imao T et al. Detection of sentinel node micrometastasis by step section and immunohistochemistry in patients with prostate cancer. J Urol 2007; 177: 1313-1317.
13. Groetelaers RP, van Berlo CL, Nijhuis PH et al. Axillary recurrences after negative sentinel lymph node biopsy under local anaesthesia for breast cancer: a follow-up study after 5 years. Eur J Surg Oncol 2009; 35: 159-163.
14. Hacker A, Jeschke S, Leeb K et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F] - fluoro choline positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006; 176: 2014-2018.
15. Hautmann S, Beitz S, Naumann M et al. Extended sentinel lymph node dissection in radical prostatectomy for prostate cancer: a study in the Kiel risk population. Urologe A 2008; 47: 299-303.
16. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
17. Heidenreich A, Varga Z, von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681-1686.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
19. Hinev A, Klissarova A, Ghenev P et al. Radioisotopic detection of sentinel lymph nodes in clinically localized high-risk prostate cancer. J BUON 2009; 14: 661-667.
20. Holl G, Dorn R, Wengenmair H et al. Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2000 patients. Eur J Nucl Med Mol Imaging 2009; 36: 1377-1382.
21. Janetschek G. Can sentinel pelvic lymph node dissection replace extended pelvic lymph node dissection in patients with prostate cancer? Nat Clin Pract Urol 2007; 4: 636-637.
22. Jeschke S, Beri A, Grull M et al. Laparoscopic radioisotope- guided sentinel lymph node dissection in staging of prostate cancer. Eur Urol 2008; 53: 126-132.
23. Kanamaru H, Oyama N, Akino H et al. Evaluation of prostate cancer using FDG-PET. Hinyokika Kiyo 2000; 46: 851-853.
24. Kettlewell S, Moyes C, Bray C et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. Br Med J 2006; 332: 1423.
25. Klitsch MC, Schenner M, Broessner C et al. Sentinel-lymphadenectomy in radical prostatectomy: Can we rely on this technique? Eur Urol Suppl 2010; 9: 265.
26. Loeb S, Carter HB. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Urol Oncol 2009; 27: 583-584.
27. MacNeill F, Mansel R, Horgan K et al. NEW START: the United Kingdom sentinel lymph biopsy training programme. A model of how multi-professional training can achieve competent national performance whilst maintaining patient safety. Breast Cancer Res Treat 2007; 106: S233.
28. Malmstrom PU. Lymph node staging in prostatic carcinoma revisited. Acta Oncol 2005; 44: 593-598.
29. Marchioro G, Vidali M, Volpe A et al. Sentinel lymph node surgery in prostate cancer:Results of a prospetctive study with a 10 years follow up. J Urol 2010; 183: e157.
30. Maza S, Taupitz M, Taymoorian K et al. Multimodal fusion imaging ensemble for targeted sentinel lymph node management: initial results of an innovative promising approach for anatomically difficult lymphatic drainage in different tumour entities. Eur J Nucl Med Mol Imaging 2007; 34: 378-383.
31. Meinhardt W, Valdes Olmos RA, van der Poel HG et al. Laparoscopic sentinel node dissection for prostate carcinoma: technical and anatomical observations. Br J Urol Int 2008; 102: 714-717.
32. Naito S, Kuroiwa K, Kinukawa N et al. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer. J Urol 2008; 180: 904-909.
33. Orwin RG. A Fail-SafeN for Effect size in metaanalysis. J Edu Behav Stat 1983; 8: 157-159.
34. Parker CC, Husband J, Dearnaley DP. Lymph node staging in clinically localized prostate cancer. Prostate Cancer Prostatic Dis 1999; 2: 191-199.
35. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-1451.
36. Picchio M, Crivellaro C, Giovacchini G et al. PETCT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging 2009; 53: 245-268.
37. Rousseau T, Lacoste J, Curtet C et al. Laparoscopic sentinel lymph node (SLN) dissection for clinically localized prostate carcinoma: Preliminary results. Eur Urol Suppl 2010; 9: 317.
38. Rusakov I, Alekseev B, Nyushko K et al. Detection of sentinel lymph nodes in prostate cancer patients. Eur Urol Suppl 2006; 5: 209.
39. Salminen E, Hogg A, Binns D et al. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002; 41: 425-429.
40. Santoro P, Lafranceschina F, Altieri ML et al. Lympho scintigraphy as alternative lymph node staging method in early prostatic carcinoma. Eur J Nucl Med Mol Imaging 2008; 35: S157.
41. Schafhauser W, Becher H, Schaffhauser R et al. Is the incidence of lymph node metastases increased with sentinel lymph node dissection in prostate cancer. J Urol Urogynäkol 2006; 13: 11-14.
42. Schilling D, Boekeler U, Gakis G et al. Modified concept for radioisotope-guided sentinel lymph node dissection in prostate cancer. World J Urol 2010.
43. Silva N Jr, Anselmi CE, Anselmi OE et al. Use of the gamma probe in sentinel lymph node biopsy in patients with prostate cancer. Nucl Med Commun 2005; 26: 1081-1086.
44. Stearns ME, Wang M, Hu Y et al. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest 2004; 84: 785-795.
45. Varga Z, Páczelt A, Balogh I et al. Nyirokcsomósebészet prosztata- és hólyagrákos betegekben. Füvészkerti Urológus Napok 2010.
46. Vermeeren L, Muller SH, Meinhardt W et al. Optimizing the colloid particle concentration for improved preoperative and intraoperative imageguided detection of sentinel nodes in prostate cancer. Eur J Nucl Med Mol Imaging 2010; 37: 1328-1334.
47. Vermeeren L, Valdes Olmos RA, Meinhardt W et al. Intraoperative radioguidance with a portable gamma camera: a novel technique for laparoscopic sentinel node localisation in urological malignancies. Eur J Nucl Med Mol Imaging 2009; 36: 1029-1036.
48. Vermeeren L, Valdes Olmos RA, Meinhardt W et al. Value of SPECT/CT for detection and anatomic localization of sentinel lymph nodes before laparoscopic sentinel node lymphadenectomy in prostate carcinoma. J Nucl Med 2009; 50: 865-870.
49. Vogt H, Schmidt M, Bares R et al. Procedure guideline for sentinel lymph node diagnosis. Nuklearmedizin 2010; 49: 167-172.
50. Vogt H, Wawroschek F, Wengenmair H et al. Sentinel lymph node diagnosis in prostatic carcinoma: I: Method and clinical evaluation. Nuklearmedizin 2002; 41: 95-101.
51. Warncke SH, Mattei A, Fuechsel FG et al. Detection rate and operating time required for gamma probeguided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging. Eur Urol 2007; 52: 126-132.
52. Wawroschek F, Hamm M, Weckermann D et al. Lymph node staging in clinically localized prostate cancer. Urol Int 2003; 71: 129-135.
53. Wawroschek F, Vogt H, Weckermann D et al. Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 2001; 166: 1715-1719.
54. Wawroschek F, Vogt H, Weckermann D et al. The sentinel lymph node concept in prostate cancer -first results of gamma probe-guided sentinel lymph node identification. Eur Urol 1999; 36: 595-600.
55. Weckermann D, Dorn R, Trefz M et al. Sentinel lymph node dissection for prostate cancer: experience with more than 1000 patients. J Urol 2007; 177: 916-920.
56. Weckermann D, Goppelt M, Dorn R et al. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progressionfree survival after radical prostatectomy. Br J Urol Int 2006; 97: 1173-1178.
57. Weckermann D, Holl G, Wagner T et al. Sentinel node dissection in prostate cancer: current status. Urologe A 2007; 46: 1500-1507.
58. 99mmTc-nanocolloid after intraprostatic injection. Nuklearmedizin 2002; 41: 102-107.
59. Woods ME, Ouwenga M, Quek ML. The role of pelvic lymphadenectomy in the management of prostate and bladder cancer. ScientificWorldJournal 2007; 7: 789-799.
60. Zamora J, Abraira V, Muriel A et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.